Short Interest in Aytu BioPharma, Inc. (NASDAQ:AYTU) Declines By 12.8%

Aytu BioPharma, Inc. (NASDAQ:AYTU) was the recipient of a significant decrease in short interest in August. As of August 15th, there was short interest totalling 324,800 shares, a decrease of 12.8% from the July 31st total of 372,500 shares. Based on an average daily trading volume, of 22,300 shares, the days-to-cover ratio is presently 14.6 days. Currently, 5.6% of the company’s stock are sold short.

Aytu BioPharma Stock Up 2.0 %

NASDAQ:AYTU traded up $0.05 during trading hours on Monday, reaching $2.50. 14,900 shares of the stock were exchanged, compared to its average volume of 20,072. The stock has a market capitalization of $14.93 million, a P/E ratio of -0.95 and a beta of -1.41. The firm has a 50 day simple moving average of $2.67 and a 200-day simple moving average of $2.90. Aytu BioPharma has a 52 week low of $1.52 and a 52 week high of $3.50.

Institutional Trading of Aytu BioPharma

A hedge fund recently bought a new stake in Aytu BioPharma stock. Armistice Capital LLC purchased a new position in shares of Aytu BioPharma, Inc. (NASDAQ:AYTU) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 252,000 shares of the company’s stock, valued at approximately $736,000. Armistice Capital LLC owned 4.22% of Aytu BioPharma at the end of the most recent quarter. Institutional investors own 33.49% of the company’s stock.

Aytu BioPharma Company Profile

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.